Edinburgh festival classical music review: Ysa�e Quartet

The odor of coffee tree, and a Haydn quartet: hard not to feel that the first daybreak chamber concert of the Edinburgh International festival was offering an oasis of civilisation in an otherwise chaotic city. The Ysa�e Quartet too supplied music to stir up the einstein up. Even the Haydn was unlawful: the C major Quartet, Op 54 No 2, which, with its through-composed middle movements and slow, serene closing curtain, subverts the usual classical pattern.

For most, nevertheless, the find will have been Szymanowski's Quartet No 2, written in 1927. Its endorsement and third base movements register the composer in proudly Polish mode: the former is a rough-edged dance driven as if by clockwork, the latter grows out of a contemplative folk-like psychogenic fugue. But the first effort is the most intriguing. It begins with a whispered, poker-faced buzz from the inner instruments, spell the low gear violin and cello tissue an angular melody or so them, and nods simultaneously towards the soft-grained textures of French impressionism and the blunt emotionality of German expressionism; perhaps the two are not so far apart.

Warm-toned in the Haydn, mercurially vivid in the Szymanowski, the players became benign automatons for Stravinsky's Three Pieces, putting a stop on almost all vibrato; these spare slight pieces seemed to deal the clockwork aspect of the Szymanowski to its logical conclusion.

Last came Debussy's Quartet, inevitably a signature work for any French tout ensemble, particularly one and only that shares a name with the work's creators (the original Ysa�e Quartet gave the premiere in 1893). From the impatient opening, through the seamlessly turning cycles of the second move to a finale that seemed a whistlestop retrospective of all that had gone earlier, this was a riveting performance.

More info

• Hudson Struggles To Keep Private Life From Public
• Tegma
• Kele 6
• Purab Ang
• Constance Demby

FDA Rejects Schering-Plough's Anaesthetic Drug Sugammadex NDA

�The U.S. FDA has issued a non-approvable letter to Schering-Plough regarding the U.S. firm's New Drug Application (NDA) for sugammadex sodium. The product (likewise marketed under the brand Bridion) is a selective relaxant binding agent that reverses the effects of neuromuscular hinder by rocuronium in general anaesthesia. In a press statement, Schering-Plough has aforesaid that the FDA's concerns over the drug ar related to hypersensitivity or allergic reactions. No issues related to the efficacy of the drug have been mentioned by the agency. Schering-Plough acquired the drug after purchasing biopharmaceutical firm Organon Biosciences in November 2007, and has since touted the experimental product as one of its main gains. Schering has noted that the product is the first base innovation in two decades in the anaesthesia segment, and has committed to working with the FDA to dissolve the issues behind the rejection.


Meanwhile, the company's cholesterol production Vytorin was once once more under the spotlight. The U.S. House Energy and Commerce Committee has asked the FDA to print details of the findings on a study conducted to examine the product's cancer risk, Reuters reports. The field found a higher cancer risk associated with patients taking Vytorin at 39 and with patients on a placebo at 23 in the closely monitored trial.

Outlook and Implications


The rejection will be a setback for Schering-Plough - more in terms of investor confidence in the short term. The company has had a serial of run-ins with regulatory agencies since cholesterol do drugs Vytorin and Zetia (ezetimibe/simvastatin and ezetimibe) were linked to potency adverse safety issues. However, the development is evenhandedly surprising given that an FDA panel gave it a confident go-ahead in March. However, although the committee gave its commendation, it did cite concerns over allergy reactions. Nevertheless, the approval was unanimous. Further, the company gained European Commission approval for marketing the drug in the European Union (EU) as Bridion. For Schering-Plough, the ontogeny will delay the realization of the benefits the U.S. strong obtained when it acquired Organon Biosciences.


From a regulatory linear perspective, the intersection is the fourth in the heel of jilted applications from the FDA that is associated with Big Pharma firms. Notably, the regulative agency had rejected Merck & Co's (U.S.) Cordaptive/Tredaptive (nicotinic acid/laropiprant), Merck and Schering-Plough's respiratory combination dose Claritin and Singulari (loratidine and montelukast), and Eli Lilly's (U.S.) long-acting version of schizophrenic psychosis drug Zyprexa (olanzapine), principally due to safety concerns. The rejection will put the agency's conservative coming to NDAs under the spotlight. Global pharmaceutical major league have already noted that the number of FDA approvals has reduced, triggered by the withdrawal of Merck's Vioxx (rofecoxib) over safety concerns. The office is under increasing pressure from the U.S. authorities, leading to a tightening of criteria for NDA approvals.

http://www.schering-plough.com


View drug information on Claritin RediTabs; Vioxx; Zyprexa.



More information

• Columnist Robert Novak Diagnosed With Brain Tumor
• Battling Aids
• Chemical clue to baby blues found
• Beware Do-It-Yourself Alzheimer’s Cures
• Does Your Voice Signal Your Desirability?

Zero 7

   
Artist: Zero 7

   Genre(s): 
Easy Listening
   Electronic
   Trip-Hop
   Techno
   

---

Discography:


   
 When It Falls

   Year: 2004   
Tracks: 11


   
 Distractions

   Year: 2002   
Tracks: 6


   
 AnotherLateNight

   Year: 2002   
Tracks: 16


   
 Simple Things

   Year: 2001   
Tracks: 12


   
 In The Waiting Line

   Year: 2001   
Tracks: 6

---

The manpower behind U.K. soulfulness turnout Zero 7 -- producers Henry Binns and Sam Hardaker -- launched their careers in the music manufacture as tea boys at a London recording studio. Soon later on, notwithstanding, both were in the fatheaded of action, working alongside a string of well-known British musicians such as the Pet Shop Boys and Robert Plant. They spent the topper character of the nineties honing their production skills behind the scenes. Then, later on taking on the identify of a nightspot in Honduras, the distich step by step began unleashing their possess ideas onto an unsuspecting populace. First came a couple of remixes; Radiohead's "Mounting Up the Walls" and Terry Callier's "Dearest Theme from Spartacus." In 1999, Zero 7 released their starting time EP, the fittingly titled EP 1. Only a smattering of copies were made and they sold out in a matter of years. A similar fate hoped-for their second gear release, EP 2. Their starting time record album, Simple Things, came out amid practically salivating from the media in mid-2001. A aggregation of mellow soul, acidulent jazz, and funk tracks, the album carried collaborations with well-thought-of vocalists Mozez, Sia Furler, and Sophie Barker. Their soph endeavour, When It Falls, appeared in March 2004, and it was followed 2 years afterwards by Garden, which included contributions from longtime favourite Sia as substantially as Swedish star José González.

Pierce on Losing Bond: "I Didn't See That Coming"

Actresses aren't the only ones dealing with ageism in Hollywood. Pierce Brosnan is feeling its effects as well -- and it hurts.

While Sean Connery and Roger Moore played James Bond well into their 50s (58 and 53, respectively), Pierce was revoked of his license to kill at age 51 for the then-37-year-old Daniel Craig, which definitely took him by surprise.

"I didn't see that coming," the actor tells Parade magazine. "I never thought of myself as being too old. It was startling to hear such things said about oneself, especially when you thought you were going down that particular avenue and then the door gets slammed in your face."

The Irish stud knew his days as 007 were numbered, but figured producers would give him one last hurrah before passing the torch.

"I thought we were going to do a fifth film," he says. "And I was going to take a gracious bow off the stage. Instead of that you're just told, 'Goodbye.'"

Now 55, Pierce has since traded in tuxes for t-shirts, living with wife Keely and their sons Dylan, 11, and Paris, 7, in Hawaii. His next flick, a big-screen production of Mamma Mia! hits theaters July 18, and he has made peace with his Bond axing.

"That's the way it goes down in life," he says. "It's as hard and as fast as that."




See Also

• WWE Chief to Give Fans $1M of His Money
• Ice Dancer Drugging Suspect Skates
• Victoria Beckham - Beckham Im A Miserable Cow
• TMZ TV Tonite — Sluts, Slots, and Sloshed

Less Gold For 'Prince'

Like last week, the top film at the box office, having already brought in less than analysts had predicted on Sunday, when the studio announced its weekend estimate, earned even less than that when the actual ticket-sales figures were finally disclosed on Monday. Although The Chronicles of Narnia: Prince Caspian was not the unmitigated disaster that Speed Racer was last week, the movie's $55.03 million take was $1.6 million below Sunday's estimate. By contrast, the No. 2 film, Iron Man earned $31.84 million, somewhat more than the $31.20 million that the studio had calculated. Overall, the weekend's top 12 films grossed $125.8 million, 28 percent below last year's $173.6 million for the comparable weekend.

The top ten films over the weekend, according to final figures compiled by Media by Numbers (figures in parentheses represent total gross to date): 1. The Chronicles of Narnia: Prince Caspian, Disney, $55,034,805, (New) ); 2. Iron Man, Paramount, $31,838,996, 3 Wks. ($223,124,385); 3. What Happens in Vegas, Fox, $13,883,874, 2 Wks. ($40,341,516); 4. Speed Racer, Warner Bros., $8,117,459, 2 Wks. ($30,284,073); 5. Made of Honor, Sony, $4,702,950, 3 Wks. ($33,903,519); 6. Baby Mama, Universal, $4,680,610, 4 Wks. ($47,343,255); 7. Forgetting Sarah Marshall, Universal, $2,786,220, 5 Wks. ($55,313,405); 8. Harold & Kumar Escape From Guantanamo Bay, Warner Bros., $1,997,450, 4 Wks. ($34,098,389); 9. The Forbidden Kingdom, Lionsgate, $1,073,856, 5 Wks. ($50,368,985); 10. The Visitor, Overture Films, $672,448, 6 Wks. ($3,388,821).


See Also

• Victoria Beckham to return to Ugly Betty
• ‘Twilight’ Actor Taylor Lautner Is Eager To Deliver ‘Naked’ Line, Master Driving
• The Game Has Car Impounded

Steroids film examines obsession with winning

NEW YORK (Reuters) - A new documentary that takes a wide-ranging look at steroid abuse suggests an American culture of winning at all costs is at odds with its public condemnation of the performance-enhancing drugs.


"Bigger, Stronger, Faster*," which opened in the United States on Friday, features interviews with gym junkies, medical experts, U.S. lawmakers and athletes such as former sprinters Carl Lewis and Ben Johnson and cyclist Floyd Landis.


But the documentary from the producers of Michael Moore's hits "Fahrenheit 9/11" and "Bowling for Columbine" also includes comical and touching first-person accounts by director Chris Bell and his confessed steroid-using weightlifting and bodybuilding brothers.


"I am basically looking at all the hypocrisy surrounding steroids," said Bell, 35, who chronicles growing up idolizing and emulating "winners" such as Sylvester Stallone and Arnold Schwarzenegger.


"Seeing all these larger-than-life heroes, I wanted to be like them and I did not know they were using steroids," he said. "Nobody wants to talk about steroids and I knew my brothers would tell me the truth so I started with them."


The film broadens its scope when it explores why steroids have a bad name -- they have legitimate medical purposes but it is illegal to use them without a prescription in the United States -- and why America obsesses over body image.


"More scrupulously reported than your average Michael Moore film but every bit as entertaining, 'Bigger, Stronger, Faster*' is as commercial as documentaries come," said Variety magazine.


The film suggests that part of the problem is a penchant for making scapegoats out of athletes like former Canadian sprinter Ben Johnson when in fact steroids can be traced back to American Olympic teams in the 1950s and 1960s. 

Joey Bishop - Rat Pack Stars Lover Mounts Legal Battle

The former partner of late RAT PACK star JOEY BISHOP has mounted a legal battle against the singer's law firm and agent.

Nora Garibotti claims Bishop's law firm and his agent Ed Hookstratten revised the star's will, meaning she missed out on inheriting Bishop's home in Newport Beach, and "books, cash, furniture and other personal property", reports TMZ.com.

She also alleges a clause was added to the will that disinherits her if she contests the will.

The suit reads, "Ms. Garibotti was a close personal friend of Joey Bishop for approximately 24 years prior to his death. For the first 16 years.... they golfed almost every day."

In 1999, at the time of Bishop's wife's death, the pair moved in together, with Bishop asking Garibotti to marry him - an offer she declined.

The suit adds, "In February, 2002, Mr. Bishop asked Ms. Garibotti to marry him, and she declined in order to avoid the publicity that she believed would interrupt their peaceful life together."

See Also

• Kim Kardashian Talks Out Of Her A*s About Burma
• Kelly Preston Reveals ‘Awkward’ Tom Cruise Sex Scene
• Mariah’s stripped down wedding